Sixfold Bioscience is a preclinical-stage biotechnology company dedicated to revolutionizing RNA therapeutics through its proprietary delivery platform, Mergo®. Founded in 2017 and based in London, Sixfold focuses on developing programmable drug delivery systems that enhance the specificity and safety profiles of RNA therapies. By integrating computational biology, artificial intelligence, and advanced chemistry, Sixfold aims to overcome the critical challenge of delivering RNA therapeutics to targeted cells beyond the liver, thereby unlocking the full potential of RNA-based treatments. Key Features and Functionality: - Mergo® Platform: A modular RNA delivery system engineered to guide RNA therapeutics to selected organs with precision, enhancing treatment efficacy and safety. - AI and Machine Learning Integration: Utilizes advanced computational tools to design and optimize RNA delivery mechanisms, ensuring adaptability and rapid development of targeted therapies. - Collaborative Research and Development: Engages in partnerships with leading academic institutions and industry experts to advance preclinical research and validate delivery systems. Primary Value and User Solutions: Sixfold Bioscience addresses the significant hurdle in RNA therapeutics: effective and safe delivery to specific cell types. By developing the Mergo® platform, Sixfold enables the targeting of RNA therapies to a broader range of tissues, moving beyond the traditional focus on liver cells. This advancement opens new avenues for treating various diseases, including cancers and genetic disorders, by delivering therapeutics directly to the affected cells. The integration of AI and machine learning accelerates the development process, allowing for rapid adaptation to emerging medical challenges and personalized treatment strategies.